狂犬病ワクチンのグローバル市場機会分析(MarketVIEW: Rabies vaccines)...市場調査レポートについてご紹介

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

★目次PDFファイル⇒http://h-and-i.main.jp/market-report/Vaczine/VAMV055.pdf

****This product is composed of a model and summary presentation

【Contents – Summary presentation (MS PowerPoint based)】

Authors Note
Executive summary
Commercial model: key outputs
Rabies vaccines: estimated PEP and PrEP treatments.
Rabies vaccines: estimated global value ($m, 2013)
Rabies vaccines: global value forecast to 2024.
Rabies vaccines: global forecast per competitor to 2024.
Rabies vaccines: global volume, 2013
Rabies vaccines: global volume forecast to 2024.
Rabies vaccines: forecast PEP and PrEP treatments.
Forecast methodology
Countries modelled in this analysis.
Rabies vaccines pricing
Future market trends
Rabies: background
Rabies: disease burden.
Rabies: disease burden per country/region
Rabies: disease burden per population
Rabies: disease burden – deaths per country/region
Rabies: disease burden – cases per population
Country/region profiles
China.
China: number of deaths 2002 to 2013
India
Other Asian markets.
US and Europe
Human and canine rabies cases, Europe, 2008-2012
LATAM
Africa
Rabies vaccine schedules
Post-exposure prophylaxis (PEP) schedules
Post-exposure prophylaxis (PEP) schedules: ID-RV
Post-exposure prophylaxis (PEP) WHO schedules
Pre-exposure prophylaxis (PrEP) schedules
Rabies vaccines: competitive landscape
Competitive landscape: Novartis/Marburg
Competitive landscape: NTV producers
Competitive landscape: per vaccine type
Competitive landscape: India/Russia DVMs
Competitive landscape: WHO prequalification
Competitive landscape: summary table
Rabies vaccines: overview of vaccine demand
China
China: estimates of total market value/volume
India
India: estimates of total market value/volume
Other Asian markets.
Other Asian markets: number of PEP treatments.
Other Asian markets: Vietnam
Other Asian markets: Thailand
Africa
Africa: South Africa
LATAM
LATAM: Brazil
Europe/US
PEP rate per 100,000 population/endemic countries
Bibliography
Disclaimer
About VacZine Analytics

※PAGES: 67 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

【Contents – Vaccine demand model(s) (MS Excel-based) – 1 model】

Title sheet
CHARTS
Global volume summary
Global value summary
Novartis (value share)
Sanofi (value share)
Novartis (volume share)
Sanofi (volume share)
Other companies (volume share)
Treatments PEP and PrEP
Country groups
EU (no risk)
EU (low risk)
US, Canada,
EU (PrEP)
US, Canada (PrEP)
Eastern Europe.
Brazil
LATAM (other)
China.
India
Indonesia
Bangladesh
Thailand
Philippines
Vietnam
Nepal
Sri Lanka
Cambodia
Myanmar
Central Asia
Africa
South Africa
Source material
Total population
Price summary
% IDRW
Estimated based PEP use
PEP summary
Estimated PEP use (Africa)
Epidemiology
China epidemiology
World Bank
Backpage

※WORKSHEETS: ~84


【レポート販売概要】

■ タイトル:狂犬病ワクチンのグローバル市場機会分析(MarketVIEW: Rabies vaccines)
■ 発行日:2014年3月
■ 調査会社:VacZine Analytics
■ 商品コード:VAMV055
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。